Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TYK Medicines, Inc. Class H ( (HK:2410) ) has issued an update.
TYK Medicines, Inc, a joint stock company incorporated in the People’s Republic of China, held its 2024 Annual General Meeting on June 26, 2025, where all proposed resolutions were passed. The meeting included the appointment of Dr. Zhu Xiangyang as a non-executive director and the re-appointment of Ernst & Young as auditors. The company’s shareholders showed strong support for the resolutions, indicating confidence in the company’s governance and future plans.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
Average Trading Volume: 2,740,401
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$7.58B
See more insights into 2410 stock on TipRanks’ Stock Analysis page.